Neoadjuvant chemotherapy with KELIM-guided surgery timing for ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests whether monitoring a tumor marker called KELIM can help doctors decide the best time for surgery in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants first receive chemotherapy to shrink tumors, then have surgery either at a planned time or later based on how the tumor marker changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer that has spread (stage IIIB, IIIC, or IVA).
- You are well enough for daily activity (ECOG performance status 0-1).
- You are not a good candidate for upfront complete surgery, or your tumor is not removable without complications.
- You have adequate organ function (bone marrow, liver, kidneys) to receive chemotherapy and have surgery.
- You are not pregnant and have no other cancer diagnosed recently (unless treated and cured).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests whether doing surgery with small incisions (minimally invasive) instead of a large cut is safe and effective for advanced ovarian cancer after chemo. It may mean a faster recovery while still removing the cancer.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.